These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16467734)

  • 21. [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
    Iino M
    Rinsho Ketsueki; 2009 Jan; 50(1):49-51. PubMed ID: 19225230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
    Galmarini CM
    Curr Opin Investig Drugs; 2006 Jun; 7(6):565-73. PubMed ID: 16784028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clofarabine.
    Pui CH; Jeha S; Kirkpatrick P
    Nat Rev Drug Discov; 2005 May; 4(5):369-70. PubMed ID: 15902772
    [No Abstract]   [Full Text] [Related]  

  • 24. Anaphylactoid reaction to high-dose methotrexate and re-administration after a successful desensitization.
    Caldeira T; Costa V; Silva I; Oliva T; Norton L
    Pediatr Hematol Oncol; 2008 Mar; 25(2):131-4. PubMed ID: 18363180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901.
    Czuczman MS; Porcu P; Johnson J; Niedzwiecki D; Kelly M; Hsi ED; Cook JR; Canellos G; Cheson BD;
    Leuk Lymphoma; 2007 Jan; 48(1):97-103. PubMed ID: 17325852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nelarabine.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nelarabine in the treatment of refractory T-cell malignant diseases.
    Kline J; Larson RA
    Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pediatric T-ALL complicated by irreversible nelarabine neurotoxicity.
    Kanayama T; Imamura T; Nakagawa N; Osone S; Hosoi H
    Pediatr Int; 2017 Jul; 59(7):843-845. PubMed ID: 28745456
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma.
    Karthik U; Motwani J
    J Oncol Pharm Pract; 2024 Apr; 30(3):594-596. PubMed ID: 38105625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma.
    Candoni A; Lazzarotto D; Petruzzellis G
    Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
    Horie R; Watanabe T; Umezawa K
    Drug News Perspect; 2006 May; 19(4):201-9. PubMed ID: 16823495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
    Gilbert J; Carducci MA; Baker SD; Dees EC; Donehower R
    Invest New Drugs; 2006 Nov; 24(6):499-508. PubMed ID: 16788861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
    Tumer TB; Ulusoy G; Adali O; Sahin G; Gozdasoglu S; Arinç E
    Am J Hematol; 2007 Oct; 82(10):906-10. PubMed ID: 17617792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multifocal necrotizing leukoencephalopathy: An unusual complication of acute leukemia.
    Robb J; Chalmers L; Rojiani A; Chamberlain M
    Arch Neurol; 2006 Jul; 63(7):1028-9. PubMed ID: 16831976
    [No Abstract]   [Full Text] [Related]  

  • 36. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
    Miller LH; Maxa KL; Winter SS; Gossai NP
    Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase I trial of nelarabine in indolent leukemias.
    Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
    J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates.
    Berg SL; Brueckner C; Nuchtern JG; Dauser R; McGuffey L; Blaney SM
    Cancer Chemother Pharmacol; 2007 May; 59(6):743-7. PubMed ID: 16953392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
    De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
    Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute T cell lymphoblastic leukemia in the recipient of a renal transplant from a donor with malignant lymphoma.
    Kowal M; Hus M; Dmoszynska A; Kocki J; Grzasko N
    Acta Haematol; 2008; 119(3):187-9. PubMed ID: 18536518
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.